Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
55 hedge funds and large institutions have $57.8M invested in Galera Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 6 closing their positions.
3,215% more call options, than puts
Call options by funds: $8.29M | Put options by funds: $250K
250% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 6
138% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 8
38% more funds holding
Funds holding: 40 → 55 (+15)
6% more capital invested
Capital invested by funds: $54.4M → $57.8M (+$3.33M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.08M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$404K |
| 3 |
Millennium Management
New York
|
+$374K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$361K |
| 5 |
Two Sigma Investments
New York
|
+$289K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$6.66M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.44M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.07M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$426K |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$278K |
GRTX Hedge Fund Activity: Q2 2023 in Review
55 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q2 2023, worth a combined $57.8M — up 6.1% from $54.4M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new GRTX positions and 6 closed out — a net gain of 15 holders — while 19 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.08M. The largest seller was Mirabella Financial Services, exiting entirely with an estimated $6.66M sold.
- 55 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q2 2023, up from 40 in Q1 2023.
- Funds reported $57.8M of Galera Therapeutics, Inc. Common Stock stock for Q2 2023, up 6.1% quarter-over-quarter.
- 21 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q2 2023 and 6 closed out, a net change of +15 holders.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q2 2023 was Vanguard Group, an estimated $1.08M added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q2 2023 was Mirabella Financial Services, an estimated $6.66M sold.
Based on aggregated 13F filings for Q2 2023.